FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2572662109> ?p ?o ?g. }

• W2572662109 endingPage "5648" @default.
• W2572662109 startingPage "5648" @default.
• W2572662109 abstract "5648 Efforts to treat pancreas cancer have been hampered by a lack of effective therapeutic options as well as predictive preclinical models. We hypothesized that nanoparticle agents encapsulating potent cytotoxic compounds may be useful against pancreatic cancer; and that antibody-targeted versions directed against EGFR may further increase efficacy against EGFR-overexpressing pancreatic cancers. We applied a liposome-based drug loading and stabilization technique to generate nanoliposomal CPT-11, a novel lipidic nanoparticle agent containing the prodrug CPT-11 (irinotecan) that has entered clinical trials. In addition, Fab9 fragments of C225 were conjugated to nanoliposomal CPT-11 to generate EGFR-targeted immunoliposomal CPT-11. Another objective of this study was to develop a bioluminescent-based orthotopic xenograft model of pancreas cancer with EGFR-overexpression to test this therapeutic approach. COLO357, a human pancreatic cell line, was passaged multiple times in vivo to generate the sub-line L3.6pl. This cell line was subsequently modified by lentiviral transduction to generate a firefly luciferase-expressing cell line, L3.6pl-T. L3.6pl-T cells were injected, during surgery, directly into the pancreas of a nude mouse to generate a tumor xenograft. Following ip administration of luciferin, animals were immediately imaged using a Xenogen IVIS 100 bioluminescent imager, and subsequently imaged at weekly intervals. Tumor burden was quantified by measuring luminescence. The signal was quantified by defining regions of interest (ROIs) and measuring photons/sec/str. Agents evaluated in this model included EGFR-targeted immunoliposomal CPT-11, nanoliposomal CPT-11, free drug or vehicle control. All treatments were administered i.v. by tail vein beginning at 7 days post- tumor implantation and continued weekly for a total of three treatments. Both nanoliposomal CPT-11 and immunoliposomal CPT-11 showed potent antitumor activity, including durable tumor regressions, and were markedly superior to the equivalent dose of free drug. While both nanoparticle constructs were highly potent, the immunoliposome agent appeared to provide more prolonged duration of responses than the non-targeted version. Systemic toxicity was not observed with any treatment. We conclude that nanoparticle-mediated delivery of CPT-11 via nanoliposomal CPT-11 or anti-EGFR immunoliposomal CPT-11 greatly enhances antitumor efficacy in the orthotopic COLO357 pancreatic xenograft model. This therapeutic approach offers potential advantages for pancreatic cancer treatment, and this type of model system may be useful in preclinical evaluation." @default.
• W2572662109 created "2017-01-26" @default.
• W2572662109 creator A5007660828 @default.
• W2572662109 creator A5016251331 @default.
• W2572662109 creator A5031306837 @default.
• W2572662109 creator A5034431014 @default.
• W2572662109 creator A5051788974 @default.
• W2572662109 creator A5059250339 @default.
• W2572662109 creator A5066525634 @default.
• W2572662109 creator A5072641295 @default.
• W2572662109 creator A5086469734 @default.
• W2572662109 creator A5074927235 @default.
• W2572662109 date "2007-05-01" @default.
• W2572662109 modified "2023-09-25" @default.
• W2572662109 title "Lipidic nanoparticle CPT-11 in a bioluminescent orthotopic pancreas cancer model" @default.
• W2572662109 hasPublicationYear "2007" @default.
• W2572662109 type Work @default.
• W2572662109 sameAs 2572662109 @default.
• W2572662109 citedByCount "1" @default.
• W2572662109 crossrefType "journal-article" @default.
• W2572662109 hasAuthorship W2572662109A5007660828 @default.
• W2572662109 hasAuthorship W2572662109A5016251331 @default.
• W2572662109 hasAuthorship W2572662109A5031306837 @default.
• W2572662109 hasAuthorship W2572662109A5034431014 @default.
• W2572662109 hasAuthorship W2572662109A5051788974 @default.
• W2572662109 hasAuthorship W2572662109A5059250339 @default.
• W2572662109 hasAuthorship W2572662109A5066525634 @default.
• W2572662109 hasAuthorship W2572662109A5072641295 @default.
• W2572662109 hasAuthorship W2572662109A5074927235 @default.
• W2572662109 hasAuthorship W2572662109A5086469734 @default.
• W2572662109 hasConcept C108215921 @default.
• W2572662109 hasConcept C111335760 @default.
• W2572662109 hasConcept C121608353 @default.
• W2572662109 hasConcept C126322002 @default.
• W2572662109 hasConcept C150903083 @default.
• W2572662109 hasConcept C185592680 @default.
• W2572662109 hasConcept C207001950 @default.
• W2572662109 hasConcept C2777996000 @default.
• W2572662109 hasConcept C2778764654 @default.
• W2572662109 hasConcept C2780210213 @default.
• W2572662109 hasConcept C2780258809 @default.
• W2572662109 hasConcept C2780259306 @default.
• W2572662109 hasConcept C502942594 @default.
• W2572662109 hasConcept C526805850 @default.
• W2572662109 hasConcept C54009773 @default.
• W2572662109 hasConcept C54355233 @default.
• W2572662109 hasConcept C71924100 @default.
• W2572662109 hasConcept C81885089 @default.
• W2572662109 hasConcept C86803240 @default.
• W2572662109 hasConcept C98274493 @default.
• W2572662109 hasConceptScore W2572662109C108215921 @default.
• W2572662109 hasConceptScore W2572662109C111335760 @default.
• W2572662109 hasConceptScore W2572662109C121608353 @default.
• W2572662109 hasConceptScore W2572662109C126322002 @default.
• W2572662109 hasConceptScore W2572662109C150903083 @default.
• W2572662109 hasConceptScore W2572662109C185592680 @default.
• W2572662109 hasConceptScore W2572662109C207001950 @default.
• W2572662109 hasConceptScore W2572662109C2777996000 @default.
• W2572662109 hasConceptScore W2572662109C2778764654 @default.
• W2572662109 hasConceptScore W2572662109C2780210213 @default.
• W2572662109 hasConceptScore W2572662109C2780258809 @default.
• W2572662109 hasConceptScore W2572662109C2780259306 @default.
• W2572662109 hasConceptScore W2572662109C502942594 @default.
• W2572662109 hasConceptScore W2572662109C526805850 @default.
• W2572662109 hasConceptScore W2572662109C54009773 @default.
• W2572662109 hasConceptScore W2572662109C54355233 @default.
• W2572662109 hasConceptScore W2572662109C71924100 @default.
• W2572662109 hasConceptScore W2572662109C81885089 @default.
• W2572662109 hasConceptScore W2572662109C86803240 @default.
• W2572662109 hasConceptScore W2572662109C98274493 @default.
• W2572662109 hasLocation W25726621091 @default.
• W2572662109 hasOpenAccess W2572662109 @default.
• W2572662109 hasPrimaryLocation W25726621091 @default.
• W2572662109 hasRelatedWork W1103933532 @default.
• W2572662109 hasRelatedWork W1966174640 @default.
• W2572662109 hasRelatedWork W1998452805 @default.
• W2572662109 hasRelatedWork W2037236698 @default.
• W2572662109 hasRelatedWork W2040448941 @default.
• W2572662109 hasRelatedWork W2042639165 @default.
• W2572662109 hasRelatedWork W2063854081 @default.
• W2572662109 hasRelatedWork W2084949476 @default.
• W2572662109 hasRelatedWork W2085690616 @default.
• W2572662109 hasRelatedWork W2120210375 @default.
• W2572662109 hasRelatedWork W2138694786 @default.
• W2572662109 hasRelatedWork W2151253787 @default.
• W2572662109 hasRelatedWork W2158134441 @default.
• W2572662109 hasRelatedWork W2784720043 @default.
• W2572662109 hasRelatedWork W2809460708 @default.
• W2572662109 hasRelatedWork W2941011349 @default.
• W2572662109 hasRelatedWork W3035520812 @default.
• W2572662109 hasRelatedWork W3088067292 @default.
• W2572662109 hasRelatedWork W3095590120 @default.
• W2572662109 hasRelatedWork W3159802446 @default.
• W2572662109 hasVolume "67" @default.
• W2572662109 isParatext "false" @default.
• W2572662109 isRetracted "false" @default.
• W2572662109 magId "2572662109" @default.
• W2572662109 workType "article" @default.